Anixa Biosciences, Inc. ANIX
At closeNov 4, 2026, 7:02 AM EST
Pre-market · Nov 4, 7:02 AM ET
- YTD
- -2.08%
- 1 year
- -23.05%
- Market cap
- 106.20M
- EPS (ttm)
- -0.32
- Shares out
- 32.18M
- Forward P/E
- -7.17
- YTD return
- -2.08%
- 1-year return
- -23.05%
- Volume
- 149.61K
- Avg volume
- 277.44K
- Open
- 3.04
- Previous close
- 2.99
- Day's range
- 3.02 – 3.19
- 52-week range
- 2.32 – 5.46
- Beta
- 0.85
- Price target
- 8.50 (+178.2%)
- Earnings date
- Jan 21, 2025
2Y -0.39 (-11.30%)
Key statistics
- Enterprise value
- 64.97M
- PEG ratio
- 0.00
- Price / book
- 3.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.30M
- Total cash
- 20.75M
- Total debt
- 237.00K
- Return on equity
- -55.24%
- Short % of float
- 1.91%
- 50-day average
- 3.17
- 200-day average
- 3.04
Analyst view
- Target (low)
- 7.00
- Target (mean)
- 8.50
- Target (high)
- 10.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Jan 21, 2025
Expected Jan 21, 2025. Consensus EPS estimate -0.11.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 21, 2025 | Oct 1, 2024 | -0.11 | — | — | — |
| Sep 6, 2024 | Jul 1, 2024 | -0.11 | -0.10 | +0.01 | +9.09% |
| Jun 4, 2024 | Apr 1, 2024 | -0.11 | -0.10 | +0.01 | +9.09% |
| Mar 12, 2024 | Jan 1, 2024 | -0.09 | -0.10 | -0.01 | -11.11% |
| Jan 16, 2024 | Oct 1, 2023 | -0.09 | -0.09 | 0.00 | 0.00% |
| Sep 6, 2023 | Jul 1, 2023 | -0.09 | -0.08 | +0.01 | +11.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 11, 2024 | D. Boral Capital | main | Buy | Buy |
| Sep 30, 2024 | EF Hutton | main | Buy | Buy |
| Sep 24, 2024 | EF Hutton | main | Buy | Buy |
| Sep 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer. Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- anixa.com
News
Anixa Biosciences Completes Dosing Of Fifth Group In Its Phase 1 Clinical Study Of FSHR-Targeted CAR-T Therapy To Treat Ovarian Cancer 
Anixa Biosciences Participant In Its Current Phase 1 Study Of FSHR-Targeted CAR-T Therapy For Recurrant Ovarian Cancer Demonstrates Stable Disease After 90 Days Of Treatment; Patient Was Treated In Fifth Dose Cohort 
Anixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer 
HC Wainwright & Co. Maintains Buy on Anixa Biosciences, Lowers Price Target to $6 - IP Australia Grants Patent To Anixa Biosciences’ Breast Cancer Vaccine Technology, Exclusively Licensed From Cleveland Clinic
Anixa Biosciences Q3 EPS $(0.08) Beats $(0.09) Estimate, Sales $0.00, Same YoY 
Anixa Biosciences To Present Data On Its Breast Cancer Vaccine At 2026 Cantor Fitzgerald Global Healthcare Conference 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Anixa Biosciences Issued Notice Of Acceptance From IP Australia For Its Breast Cancer Vaccine Technology 
Anixa Biosciences Doses First Participant In Fifth Group Of Its Phase 1 Clinical Study Of CAR-T/CER-T Therapy For Recurrent Ovarian Cancer
Your note
Sign in to keep a note on ANIX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASKIES ARNOLD M | Director | Purchase | Jul 25, 2024 | 115,000 |
| CATELANI MICHAEL J | President | Purchase | Jun 6, 2024 | 35,211 |
| KUMAR AMIT | Chief Executive Officer | Purchase | Jun 6, 2024 | 516,925 |
| TITTERTON LEWIS H JR | Director | Conversion of Exercise of derivative security | Oct 21, 2024 | 912,334 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.33% | 1,392,906 | 3.59M | Sep 29, 2024 |
| D.A. Davidson & Co. | 2.09% | 671,072 | 1.73M | Sep 29, 2024 |
| Laird Norton Wetherby Trust Company, LLC | 1.93% | 620,735 | 1.60M | Sep 29, 2024 |
| UBS Group AG | 1.65% | 529,398 | 1.37M | Sep 29, 2024 |
| Mission Wealth Management, LLC | 1.58% | 509,517 | 1.31M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.02% | 328,778 | 848.25K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.88% | 927,841 | 2.39M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.31% | 420,658 | 1.09M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.54% | 172,262 | 444.44K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.22% | 72,221 | 186.33K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.17% | 53,550 | 138.16K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 41,099 | 106.03K | Oct 30, 2024 |